15.21 USD
-0.16
1.04%
At close Aug 25, 4:00 PM EDT
After hours
15.35
+0.14
0.92%
1 day
-1.04%
5 days
0.80%
1 month
7.34%
3 months
43.22%
6 months
-3.73%
Year to date
-8.98%
1 year
-22.04%
5 years
-26.09%
10 years
83.03%
 

About: The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

Employees: 6,000

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

80% more repeat investments, than reductions

Existing positions increased: 157 | Existing positions reduced: 87

67% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 5 (+2) [Q2]

51% more call options, than puts

Call options by funds: $22.5M | Put options by funds: $14.8M

36% more first-time investments, than exits

New positions opened: 80 | Existing positions closed: 59

7.2% more ownership

Funds ownership: 92.28% [Q1] → 99.47% (+7.2%) [Q2]

3% more funds holding

Funds holding: 415 [Q1] → 427 (+12) [Q2]

9% less capital invested

Capital invested by funds: $1.87B [Q1] → $1.71B (-$160M) [Q2]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$13
15%
downside
Avg. target
$14.67
4%
downside
High target
$16
5%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Mizuho
John Roberts
5%upside
$16
Outperform
Maintained
15 Jul 2025
RBC Capital
Arun Viswanathan
1%downside
$15
Outperform
Maintained
3 Jul 2025
Barclays
Michael Leithead
15%downside
$13
Equal-Weight
Maintained
28 May 2025

Financial journalist opinion

Based on 14 articles about CC published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Chemours Enters Strategic Agreement With SRF to Boost Supply
CC partners with SRF to expand global supply chain, boost operational flexibility and strengthen its high-value product mix.
Chemours Enters Strategic Agreement With SRF to Boost Supply
Neutral
Business Wire
1 week ago
Chemours and SRF Limited Announce Strategic Agreements in India to Support Market Needs for Essential Applications by 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours and SRF Limited Announce Strategic Agreements in India to Support Market Needs for Essential Applications by 2026.
Chemours and SRF Limited Announce Strategic Agreements in India to Support Market Needs for Essential Applications by 2026
Neutral
Business Wire
1 week ago
Samsung Electronics Successfully Qualifies Chemours' Opteon™ Two-Phase Immersion Cooling Fluid
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Samsung Electronics Successfully Qualifies Chemours' Opteon™ Two-Phase Immersion Cooling Fluid.
Samsung Electronics Successfully Qualifies Chemours' Opteon™ Two-Phase Immersion Cooling Fluid
Positive
Zacks Investment Research
1 week ago
Chemours Q2 Earnings & Revenues Beat Estimates on Higher Volumes
CC posts Q2 earnings and sales beat driven by volume and pricing gains, but issues softer sequential guidance.
Chemours Q2 Earnings & Revenues Beat Estimates on Higher Volumes
Positive
Seeking Alpha
2 weeks ago
Chemours: Solid Q2 And Legal Progress Are Bullish (Rating Upgrade)
Chemours is showing financial improvement, especially in Opteon refrigerants, despite industry headwinds and a recent dividend cut. The company's legal overhang is easing after a favorable New Jersey PFAS settlement, freeing up future cash flow and reducing uncertainty. Balance sheet leverage remains high, but improving free cash flow in the second half should reduce net debt and support the current dividend.
Chemours: Solid Q2 And Legal Progress Are Bullish (Rating Upgrade)
Positive
The Motley Fool
2 weeks ago
Chemours (CC) Q2 EPS Jumps 53%
Chemours (CC) Q2 EPS Jumps 53%
Chemours (CC) Q2 EPS Jumps 53%
Neutral
Seeking Alpha
2 weeks ago
The Chemours Company (CC) Q2 2025 Earnings Call Transcript
The Chemours Company (NYSE:CC ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Brandon Ontjes - Vice President of Investor Relations Denise M. Dignam - President, CEO & Director Shane W.
The Chemours Company (CC) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
2 weeks ago
Chemours (CC) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Reports Q2 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
2 weeks ago
Chemours (CC) Tops Q2 Earnings and Revenue Estimates
Chemours (CC) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.38 per share a year ago.
Chemours (CC) Tops Q2 Earnings and Revenue Estimates
Neutral
Business Wire
2 weeks ago
The Chemours Company Reports Second Quarter 2025 Results
WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--The Chemours Company Reports Second Quarter 2025 Results.
The Chemours Company Reports Second Quarter 2025 Results
Charts implemented using Lightweight Charts™